KRAS and neoplasm: Attempting to design and develop drugs specifically targeting each individual RAS mutation would be extremely challenging and time-consuming, so direct targeting of ligand binding sites conserved on all RAS proteins (KRAS4A, 4B, NRAS and HRAS) has been thought to be one potential method of inhibiting RAS across all mutation and tumour types.